The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | MRD: a promising biomarker in multiple myeloma
In this video, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses the role of measurable residual disease (MRD) as a promising biomarker in multiple myeloma, and further highlights clinical trials supporting the use of MRD. Dr Corre emphasizes the improved progression-free survival (PFS) observed in patients who achieve MRD negativity, and further highlights clinical trials investigating MRD in myeloma, including the Cassiopeia trial (NCT02541383) and the MIDAS trial (NCT04934475), and also discusses the importance of post-induction timepoints. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
